Article
Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
The Journal of infectious diseases - 17 Sept 2021
Santos Bravo Marta, Plault Nicolas, Sánchez Palomino Sonsoles, Mosquera Gutierrez María Mar, Fernández Avilés Francesc, Suarez Lledo María, Sabé Fernández Nuria, Rovira Montserrat, Alain Sophie, Marcos Maeso M Ángeles
Abstract excerpt
Two transplant recipients (1 kidney and 1 hematopoietic stem cell) received maribavir (MBV) after cytomegalovirus (CMV) infection clinically resistant to standard therapy. Both patients achieved CMV DNA clearance within 30 and 18 days; however, the UL97 C480F variant emerged, causing recurrent CMV infection after a cumulative 2 months of MBV and 15 or 4 weeks of ganciclovir treatment, respectively. C480F was not...
Topics
- Adult
- Antiviral Agents
- Benzimidazoles
- Cytomegalovirus
- Cytomegalovirus Infections
- Drug Resistance, Viral
- Female
- Ganciclovir
- Hematopoietic Stem Cell Transplantation